EBV Clinical Trial
Official title:
Comparison of Abbott Architect®, Siemens Immulite®, and Diasorin Liaison® for Determination of Epstein-Barr Virus Serological Diagnosis
This study compared the performance of three automated immunoassays, Architect (Abbott), Immulite (Siemens) and Liaison (Diasorin), for Epstein-Barr virus (EBV) serology. Ninety-one serum samples collected in Amiens University Hospital were analyzed for the presence of Viral Capsid Antigen (VCA) IgG and IgM and Epstein-Barr Nuclear Antigen (EBNA) IgG. The agreement between the three assays was calculated for each marker individually and for determination of the EBV profile, based on interpretation of the combination of these three EBV markers.
This retrospective study was conducted on 91 samples collected between 2014 and 2015 for
which EBV diagnosis was requested. The serological diagnosis of EBV infection was performed
in the Amiens University Hospital virology laboratory (France). The median age of patients
was 34 years (mean: 38 years, range: 3-82 year) with a sex ratio of 50%. Sixteen of the 91
samples concerned children (<15 years).
This study compared the performance of three automated immunoassays, Architect (Abbott),
Immulite (Siemens) and Liaison (Diasorin), for Epstein-Barr virus (EBV) serology. Ninety-one
serum samples collected in Amiens University Hospital were analyzed for the presence of Viral
Capsid Antigen (VCA) IgG and IgM and Epstein-Barr Nuclear Antigen (EBNA) IgG. The agreement
between the three assays was calculated for each marker individually and for determination of
the EBV profile, based on interpretation of the combination of these three EBV markers.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02878278 -
Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation
|
Phase 2 | |
| Terminated |
NCT01948180 -
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
|
Phase 2 | |
| Completed |
NCT01923766 -
Cytotoxic T Cells to Prevent Virus Infections
|
Phase 1 | |
| Terminated |
NCT03699904 -
Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial
|
Phase 2 | |
| Recruiting |
NCT01011712 -
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
|
||
| Active, not recruiting |
NCT04645147 -
Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
|
Phase 1 | |
| Terminated |
NCT02080416 -
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
|
Phase 0 | |
| Completed |
NCT02213068 -
Belatacept 3 Month Post Transplant Conversion Study
|
Phase 4 | |
| Recruiting |
NCT02779439 -
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
|
Phase 1 | |
| Not yet recruiting |
NCT05677178 -
Response Prediction in EBV-HLH Using Metabonomics Analysis
|
||
| Active, not recruiting |
NCT01945814 -
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
|
Phase 1 | |
| Recruiting |
NCT02007356 -
A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
|
Phase 2 | |
| Completed |
NCT03755440 -
PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.
|
Phase 2 | |
| Completed |
NCT03973723 -
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
|
||
| Completed |
NCT02318030 -
CNTRP POSITIVE Study
|